Guardant Health, Inc. (GH) stock
GHNasdaqServices-Medical LaboratoriesFiscal year ends December 31
$145.14+1.86 (+1.30%)
Close on Nov 18, 2026Market cap $19.48BP/E –Yield –
Guardant Health free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Guardant Health's free cash flow for the twelve months ending Jun 30, 2026 was -$240.72M. For fiscal 2025 it was -$233.07M. The highest annual figure on record is -$38.48M in fiscal 2016.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$233.07M | – |
| FY2024 | Dec 31, 2024 | -$274.94M | – |
| FY2023 | Dec 31, 2023 | -$345.46M | – |
| FY2022 | Dec 31, 2022 | -$386.92M | – |
| FY2021 | Dec 31, 2021 | -$284.05M | – |
| FY2020 | Dec 31, 2020 | -$140.10M | – |
| FY2019 | Dec 31, 2019 | -$65.85M | – |
| FY2018 | Dec 31, 2018 | -$92.39M | – |
| FY2017 | Dec 31, 2017 | -$78.92M | – |
| FY2016 | Dec 31, 2016 | -$38.48M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$69.54M | – |
| Q1 FY2026 | Mar 31, 2026 | -$71.20M | – |
| Q4 FY2025 | Dec 31, 2025 | -$54.22M | – |
| Q3 FY2025 | Sep 30, 2025 | -$45.76M | – |
| Q2 FY2025 | Jun 30, 2025 | -$65.93M | – |
| Q1 FY2025 | Mar 31, 2025 | -$67.15M | – |
| Q4 FY2024 | Dec 31, 2024 | -$83.39M | – |
| Q3 FY2024 | Sep 30, 2024 | -$55.26M | – |
| Q2 FY2024 | Jun 30, 2024 | -$99.08M | – |
| Q1 FY2024 | Mar 31, 2024 | -$37.22M | – |
| Q4 FY2023 | Dec 31, 2023 | -$82.81M | – |
| Q3 FY2023 | Sep 30, 2023 | -$80.16M | – |
| Q2 FY2023 | Jun 30, 2023 | -$100.53M | – |
| Q1 FY2023 | Mar 31, 2023 | -$81.97M | – |
| Q4 FY2022 | Dec 31, 2022 | -$100.75M | – |
| Q3 FY2022 | Sep 30, 2022 | -$99.89M | – |
| Q2 FY2022 | Jun 30, 2022 | -$134.97M | – |
| Q1 FY2022 | Mar 31, 2022 | -$51.32M | – |
| Q4 FY2021 | Dec 31, 2021 | -$101.61M | – |
| Q3 FY2021 | Sep 30, 2021 | -$75.29M | – |
| Q2 FY2021 | Jun 30, 2021 | -$81.27M | – |
| Q1 FY2021 | Mar 31, 2021 | -$25.88M | – |
| Q4 FY2020 | Dec 31, 2020 | -$66.51M | – |
| Q3 FY2020 | Sep 30, 2020 | -$17.84M | – |
| Q2 FY2020 | Jun 30, 2020 | -$32.87M | – |
| Q1 FY2020 | Mar 31, 2020 | -$22.88M | – |
| Q4 FY2019 | Dec 31, 2019 | -$37.43M | – |
| Q3 FY2019 | Sep 30, 2019 | -$4.53M | – |
| Q2 FY2019 | Jun 30, 2019 | -$16.88M | – |
| Q1 FY2019 | Mar 31, 2019 | -$7.01M | – |
| Q4 FY2018 | Dec 31, 2018 | -$29.47M | – |
| Q3 FY2018 | Sep 30, 2018 | -$27.96M | – |
| Q2 FY2018 | Jun 30, 2018 | -$24.38M | – |
| Q1 FY2018 | Mar 31, 2018 | -$10.58M | – |
| Q4 FY2017 | Dec 31, 2017 | -$20.95M | – |
See a number that looks wrong?